Fig. 2From: Safety of coagulation factor concentrates guided by ROTEM™-analyses in liver transplantation: results from 372 proceduresBlood product use in survivors and nonsurvivors of orthotopic liver transplantation. Nonsurvivors were more likely to receive fibrinogen concentrates, PCC, platelet concentrates, and red blood cell concentrates. Differences between groups were evaluated using the unpaired Wilcoxon test. (PCC: prothrombin complex concentrate; RBC: red blood cell concentrate)Back to article page